메뉴 건너뛰기




Volumn 15, Issue 1, 2014, Pages 1-15

The use of statins in people at risk of developing diabetes mellitus: Evidence and guidance for clinical practice

(31)  Sattar, Naveed A a   Ginsberg, Henry b   Ray, Kausik c   Chapman, M John d   Arca, Marcello e   Averna, Maurizio f   Betteridge, D John g   Bhatnagar, Deepak h   Bilianou, Elena i   Carmena, Rafael j   Češka, Richard k   Corsini, Alberto l   Erbel, Raimund m   Flynn, Paul D n   Garcia Moll, Xavier o   Gumprecht, Janusz p   Ishibashi, Shun q   Jambart, Selim r   Kastelein, John J P s   Maher, Vincent t   more..


Author keywords

Cardiovascular; CVD; Diabetes; Diabetogenicity; Statins; T2D

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; ATORVASTATIN; CHYLOMICRON; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; PITAVASTATIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; STATIN (PROTEIN); VERY LOW DENSITY LIPOPROTEIN; GLYCOSYLATED HEMOGLOBIN; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

EID: 84900802536     PISSN: 15675688     EISSN: 18785050     Source Type: Journal    
DOI: 10.1016/j.atherosclerosissup.2014.04.001     Document Type: Article
Times cited : (89)

References (111)
  • 2
    • 84877642098 scopus 로고    scopus 로고
    • European guidelines on cardiovascular disease prevention in clinical practice (Version 2012): the Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice
    • Perk J., De B.G., Gohlke H., et al. European guidelines on cardiovascular disease prevention in clinical practice (Version 2012): the Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. Int J Behav Med 2012, 19:403-488.
    • (2012) Int J Behav Med , vol.19 , pp. 403-488
    • Perk, J.1    De, B.G.2    Gohlke, H.3
  • 3
    • 79960539641 scopus 로고    scopus 로고
    • ESC/EAS guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)
    • Reiner Z., Catapano A.L., De B.G., et al. ESC/EAS guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 2011, 32:1769-1818.
    • (2011) Eur Heart J , vol.32 , pp. 1769-1818
    • Reiner, Z.1    Catapano, A.L.2    De, B.G.3
  • 4
    • 84892649479 scopus 로고    scopus 로고
    • Standards of medical care in diabetes-2014
    • Standards of medical care in diabetes-2014. Diabetes Care 2014, 37(Suppl. 1):S14-S80.
    • (2014) Diabetes Care , vol.37 , Issue.SUPPL. 1
  • 5
    • 33646387174 scopus 로고    scopus 로고
    • Total cardiovascular risk: a new treatment concept
    • Mancia G. Total cardiovascular risk: a new treatment concept. J Hypertens Suppl 2006, 24:S17-S24.
    • (2006) J Hypertens Suppl , vol.24
    • Mancia, G.1
  • 6
    • 77956960932 scopus 로고    scopus 로고
    • 30-year trends in serum lipids among United States adults: results from the National Health and Nutrition Examination Surveys II, III, and 1999-2006
    • Cohen J.D., Cziraky M.J., Cai Q., et al. 30-year trends in serum lipids among United States adults: results from the National Health and Nutrition Examination Surveys II, III, and 1999-2006. Am J Cardiol 2010, 106:969-975.
    • (2010) Am J Cardiol , vol.106 , pp. 969-975
    • Cohen, J.D.1    Cziraky, M.J.2    Cai, Q.3
  • 7
    • 4444382796 scopus 로고    scopus 로고
    • Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study
    • Yusuf S., Hawken S., Ounpuu S., et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004, 364:937-952.
    • (2004) Lancet , vol.364 , pp. 937-952
    • Yusuf, S.1    Hawken, S.2    Ounpuu, S.3
  • 8
    • 84885997413 scopus 로고    scopus 로고
    • ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD)
    • Ryden L., Grant P.J., Anker S.D., et al. ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). Eur Heart J 2013, 34:3035-3087.
    • (2013) Eur Heart J , vol.34 , pp. 3035-3087
    • Ryden, L.1    Grant, P.J.2    Anker, S.D.3
  • 9
    • 4544275379 scopus 로고    scopus 로고
    • Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines
    • Grundy S.M., Cleeman J.I., Merz C.N., et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. J Am Coll Cardiol 2004, 44:720-732.
    • (2004) J Am Coll Cardiol , vol.44 , pp. 720-732
    • Grundy, S.M.1    Cleeman, J.I.2    Merz, C.N.3
  • 10
    • 84881100168 scopus 로고    scopus 로고
    • Statins in the primary prevention of cardiovascular disease
    • Reiner Z. Statins in the primary prevention of cardiovascular disease. Nat Rev Cardiol 2013, 10:453-464.
    • (2013) Nat Rev Cardiol , vol.10 , pp. 453-464
    • Reiner, Z.1
  • 11
    • 84903184698 scopus 로고    scopus 로고
    • 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines
    • Epub ahead of print. Available at:
    • Stone N.J., Robinson J., Lichtenstein A.H., et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2013, Epub ahead of print. Available at:. http://circ.ahajournals.org/content/early/2013/11/11/01.cir.0000437738.63853.7a.long.
    • (2013) Circulation
    • Stone, N.J.1    Robinson, J.2    Lichtenstein, A.H.3
  • 12
    • 78049237390 scopus 로고    scopus 로고
    • EUROASPIRE III. Management of cardiovascular risk factors in asymptomatic high-risk patients in general practice: cross-sectional survey in 12 European countries
    • Kotseva K., Wood D., De B.G., et al. EUROASPIRE III. Management of cardiovascular risk factors in asymptomatic high-risk patients in general practice: cross-sectional survey in 12 European countries. Eur J Cardiovasc Prev Rehabil 2010, 17:530-540.
    • (2010) Eur J Cardiovasc Prev Rehabil , vol.17 , pp. 530-540
    • Kotseva, K.1    Wood, D.2    De, B.G.3
  • 13
    • 84884404691 scopus 로고    scopus 로고
    • Trends in age-specific coronary heart disease mortality in the European Union over three decades: 1980-2009
    • Nichols M., Townsend N., Scarborough P., et al. Trends in age-specific coronary heart disease mortality in the European Union over three decades: 1980-2009. Eur Heart J 2013, 34:3017-3027.
    • (2013) Eur Heart J , vol.34 , pp. 3017-3027
    • Nichols, M.1    Townsend, N.2    Scarborough, P.3
  • 14
    • 84861537866 scopus 로고    scopus 로고
    • The effect of elevated body mass index on ischemic heart disease risk: causal estimates from a Mendelian randomisation approach
    • Nordestgaard B.G., Palmer T.M., Benn M., et al. The effect of elevated body mass index on ischemic heart disease risk: causal estimates from a Mendelian randomisation approach. PLoS Med 2012, 9:e1001212.
    • (2012) PLoS Med , vol.9
    • Nordestgaard, B.G.1    Palmer, T.M.2    Benn, M.3
  • 15
    • 84875389379 scopus 로고    scopus 로고
    • International Diabetes Federation, Available at:
    • International Diabetes Federation Global guidelines for Type 2 diabetes 2012, Available at:. http://www.idf.org/sites/default/files/IDF%20Guideline%20for%20Type%202%20Diabetes.pdf.
    • (2012) Global guidelines for Type 2 diabetes
  • 16
    • 33845338724 scopus 로고    scopus 로고
    • Projections of global mortality and burden of disease from 2002 to 2030
    • Mathers C.D., Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med 2006, 3:e442.
    • (2006) PLoS Med , vol.3
    • Mathers, C.D.1    Loncar, D.2
  • 17
    • 77951049833 scopus 로고    scopus 로고
    • Take action to prevent diabetes-the IMAGE toolkit for the prevention of type 2 diabetes in Europe
    • Lindstrom J., Neumann A., Sheppard K.E., et al. Take action to prevent diabetes-the IMAGE toolkit for the prevention of type 2 diabetes in Europe. Horm Metab Res 2010, 42(Suppl. 1):S37-S55.
    • (2010) Horm Metab Res , vol.42 , Issue.SUPPL. 1
    • Lindstrom, J.1    Neumann, A.2    Sheppard, K.E.3
  • 18
    • 77955014011 scopus 로고    scopus 로고
    • Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study
    • O'Donnell M.J., Xavier D., Liu L., et al. Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study. Lancet 2010, 376:112-123.
    • (2010) Lancet , vol.376 , pp. 112-123
    • O'Donnell, M.J.1    Xavier, D.2    Liu, L.3
  • 19
    • 26244432388 scopus 로고    scopus 로고
    • Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins
    • Baigent C., Keech A., Kearney P.M., et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005, 366:1267-1278.
    • (2005) Lancet , vol.366 , pp. 1267-1278
    • Baigent, C.1    Keech, A.2    Kearney, P.M.3
  • 20
    • 78449281377 scopus 로고    scopus 로고
    • Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials
    • Baigent C., Blackwell L., Emberson J., et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010, 376:1670-1681.
    • (2010) Lancet , vol.376 , pp. 1670-1681
    • Baigent, C.1    Blackwell, L.2    Emberson, J.3
  • 21
    • 38049033935 scopus 로고    scopus 로고
    • Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis
    • Kearney P.M., Blackwell L., Collins R., et al. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 2008, 371:117-125.
    • (2008) Lancet , vol.371 , pp. 117-125
    • Kearney, P.M.1    Blackwell, L.2    Collins, R.3
  • 22
    • 84864832599 scopus 로고    scopus 로고
    • The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials
    • Mihaylova B., Emberson J., Blackwell L., et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet 2012, 380:581-590.
    • (2012) Lancet , vol.380 , pp. 581-590
    • Mihaylova, B.1    Emberson, J.2    Blackwell, L.3
  • 23
    • 79953836812 scopus 로고    scopus 로고
    • Cardiovascular event reduction and adverse events among subjects attaining low-density lipoprotein cholesterol <50 mg/dl with rosuvastatin. The JUPITER trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin)
    • Hsia J., MacFadyen J.G., Monyak J., et al. Cardiovascular event reduction and adverse events among subjects attaining low-density lipoprotein cholesterol <50 mg/dl with rosuvastatin. The JUPITER trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin). J Am Coll Cardiol 2011, 57:1666-1675.
    • (2011) J Am Coll Cardiol , vol.57 , pp. 1666-1675
    • Hsia, J.1    MacFadyen, J.G.2    Monyak, J.3
  • 24
    • 84874812584 scopus 로고    scopus 로고
    • Statins for the primary prevention of cardiovascular disease
    • Available at:
    • Taylor F., Huffman M.D., Macedo A.F., et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev 2013, 1:CD004816. Available at:. http://www.ncbi.nlm.nih.gov/pubmed/23440795.
    • (2013) Cochrane Database Syst Rev , vol.1
    • Taylor, F.1    Huffman, M.D.2    Macedo, A.F.3
  • 25
    • 33645524176 scopus 로고    scopus 로고
    • Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial
    • Nissen S.E., Nicholls S.J., Sipahi I., et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. J Am Med Assoc 2006, 295:1556-1565.
    • (2006) J Am Med Assoc , vol.295 , pp. 1556-1565
    • Nissen, S.E.1    Nicholls, S.J.2    Sipahi, I.3
  • 26
    • 82555168428 scopus 로고    scopus 로고
    • Effect of two intensive statin regimens on progression of coronary disease
    • Nicholls S.J., Ballantyne C.M., Barter P.J., et al. Effect of two intensive statin regimens on progression of coronary disease. N Engl J Med 2011, 365:2078-2087.
    • (2011) N Engl J Med , vol.365 , pp. 2078-2087
    • Nicholls, S.J.1    Ballantyne, C.M.2    Barter, P.J.3
  • 27
    • 84856104984 scopus 로고    scopus 로고
    • Adverse events associated with individual statin treatments for cardiovascular disease: an indirect comparison meta-analysis
    • Alberton M., Wu P., Druyts E., et al. Adverse events associated with individual statin treatments for cardiovascular disease: an indirect comparison meta-analysis. QJM 2012, 105:145-157.
    • (2012) QJM , vol.105 , pp. 145-157
    • Alberton, M.1    Wu, P.2    Druyts, E.3
  • 28
    • 0038645309 scopus 로고    scopus 로고
    • Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial)
    • Jones P.H., Davidson M.H., Stein E.A., et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). Am J Cardiol 2003, 92:152-160.
    • (2003) Am J Cardiol , vol.92 , pp. 152-160
    • Jones, P.H.1    Davidson, M.H.2    Stein, E.A.3
  • 29
    • 33845876333 scopus 로고    scopus 로고
    • Risks associated with statin therapy: a systematic overview of randomized clinical trials
    • Kashani A., Phillips C.O., Foody J.M., et al. Risks associated with statin therapy: a systematic overview of randomized clinical trials. Circulation 2006, 114:2788-2797.
    • (2006) Circulation , vol.114 , pp. 2788-2797
    • Kashani, A.1    Phillips, C.O.2    Foody, J.M.3
  • 30
    • 29944446607 scopus 로고    scopus 로고
    • Statins and cancer risk: a meta-analysis
    • Dale K.M., Coleman C.I., Henyan N.N., et al. Statins and cancer risk: a meta-analysis. J Am Med Assoc 2006, 295:74-80.
    • (2006) J Am Med Assoc , vol.295 , pp. 74-80
    • Dale, K.M.1    Coleman, C.I.2    Henyan, N.N.3
  • 31
    • 0034015649 scopus 로고    scopus 로고
    • Effects of lovastatin on cognitive function and psychological well-being
    • Muldoon M.F., Barger S.D., Ryan C.M., et al. Effects of lovastatin on cognitive function and psychological well-being. Am J Med 2000, 108:538-546.
    • (2000) Am J Med , vol.108 , pp. 538-546
    • Muldoon, M.F.1    Barger, S.D.2    Ryan, C.M.3
  • 32
  • 33
    • 84865197598 scopus 로고    scopus 로고
    • A survey of the FDA's AERS database regarding muscle and tendon adverse events linked to the statin drug class
    • Hoffman K.B., Kraus C., Dimbil M., et al. A survey of the FDA's AERS database regarding muscle and tendon adverse events linked to the statin drug class. PLoS One 2012, 7:e42866.
    • (2012) PLoS One , vol.7
    • Hoffman, K.B.1    Kraus, C.2    Dimbil, M.3
  • 34
    • 84900795257 scopus 로고    scopus 로고
    • Merck & Co., Available at:
    • Merck & Co. Simvastatin (Zocor) Prescribing Information 2013, Available at:. http://www.merck.com/product/usa/pi_circulars/z/zocor/zocor_pi.pdf.
    • (2013) Simvastatin (Zocor) Prescribing Information
  • 35
    • 84864861863 scopus 로고    scopus 로고
    • Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial
    • Ridker P.M., Pradhan A., MacFadyen J.G., et al. Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial. Lancet 2012, 380:565-571.
    • (2012) Lancet , vol.380 , pp. 565-571
    • Ridker, P.M.1    Pradhan, A.2    MacFadyen, J.G.3
  • 36
    • 56749106312 scopus 로고    scopus 로고
    • Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein
    • Ridker P.M., Danielson E., Fonseca F.A., et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008, 359:2195-2207.
    • (2008) N Engl J Med , vol.359 , pp. 2195-2207
    • Ridker, P.M.1    Danielson, E.2    Fonseca, F.A.3
  • 37
    • 0035936527 scopus 로고    scopus 로고
    • Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study
    • Freeman D.J., Norrie J., Sattar N., et al. Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation 2001, 103:357-362.
    • (2001) Circulation , vol.103 , pp. 357-362
    • Freeman, D.J.1    Norrie, J.2    Sattar, N.3
  • 38
    • 79959428660 scopus 로고    scopus 로고
    • Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis
    • Preiss D., Seshasai S.R., Welsh P., et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. J Am Med Assoc 2011, 305:2556-2564.
    • (2011) J Am Med Assoc , vol.305 , pp. 2556-2564
    • Preiss, D.1    Seshasai, S.R.2    Welsh, P.3
  • 39
    • 77549087054 scopus 로고    scopus 로고
    • Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials
    • Sattar N., Preiss D., Murray H.M., et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet 2010, 375:735-742.
    • (2010) Lancet , vol.375 , pp. 735-742
    • Sattar, N.1    Preiss, D.2    Murray, H.M.3
  • 40
    • 84865562586 scopus 로고    scopus 로고
    • Statins are diabetogenic-myth or reality?
    • Sattar N., Taskinen M.R. Statins are diabetogenic-myth or reality?. Atheroscler Suppl 2012, 13:1-10.
    • (2012) Atheroscler Suppl , vol.13 , pp. 1-10
    • Sattar, N.1    Taskinen, M.R.2
  • 41
    • 79953183649 scopus 로고    scopus 로고
    • Predictors of new-onset diabetes in patients treated with atorvastatin: results from 3 large randomized clinical trials
    • Waters D.D., Ho J.E., DeMicco D.A., et al. Predictors of new-onset diabetes in patients treated with atorvastatin: results from 3 large randomized clinical trials. J Am Coll Cardiol 2011, 57:1535-1545.
    • (2011) J Am Coll Cardiol , vol.57 , pp. 1535-1545
    • Waters, D.D.1    Ho, J.E.2    DeMicco, D.A.3
  • 42
    • 84873738693 scopus 로고    scopus 로고
    • Statins and diabetes risk: fact, fiction, and clinical implications
    • Rocco M.B. Statins and diabetes risk: fact, fiction, and clinical implications. Cleve Clin J Med 2012, 79:883-893.
    • (2012) Cleve Clin J Med , vol.79 , pp. 883-893
    • Rocco, M.B.1
  • 44
    • 84878773567 scopus 로고    scopus 로고
    • Risk of incident diabetes among patients treated with statins: population based study
    • Carter A.A., Gomes T., Camacho X., et al. Risk of incident diabetes among patients treated with statins: population based study. Brit Med J 2013, 346:f2610.
    • (2013) Brit Med J , vol.346
    • Carter, A.A.1    Gomes, T.2    Camacho, X.3
  • 45
    • 84875065352 scopus 로고    scopus 로고
    • Statins and risk of treated incident diabetes in a primary care population
    • Zaharan N.L., Williams D., Bennett K. Statins and risk of treated incident diabetes in a primary care population. Br J Clin Pharmacol 2013, 75:1118-1124.
    • (2013) Br J Clin Pharmacol , vol.75 , pp. 1118-1124
    • Zaharan, N.L.1    Williams, D.2    Bennett, K.3
  • 46
    • 0037164314 scopus 로고    scopus 로고
    • Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial
    • Shepherd J., Blauw G.J., Murphy M.B., et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002, 360:1623-1630.
    • (2002) Lancet , vol.360 , pp. 1623-1630
    • Shepherd, J.1    Blauw, G.J.2    Murphy, M.B.3
  • 47
    • 78751680407 scopus 로고    scopus 로고
    • Efficacy and safety of statin treatment for cardiovascular disease: a network meta-analysis of 170,255 patients from 76 randomized trials
    • Mills E.J., Wu P., Chong G., et al. Efficacy and safety of statin treatment for cardiovascular disease: a network meta-analysis of 170,255 patients from 76 randomized trials. QJM 2011, 104:109-124.
    • (2011) QJM , vol.104 , pp. 109-124
    • Mills, E.J.1    Wu, P.2    Chong, G.3
  • 48
    • 84885942051 scopus 로고    scopus 로고
    • Statin diabetogenicity: guidance for clinicians
    • Ray K. Statin diabetogenicity: guidance for clinicians. Cardiovasc Diabetol 2013, 12(Suppl. 1):S3.
    • (2013) Cardiovasc Diabetol , vol.12 , Issue.SUPPL. 1
    • Ray, K.1
  • 49
    • 84886059217 scopus 로고    scopus 로고
    • All-cause and cardiovascular mortality in middle-aged people with Type 2 diabetes compared with people without diabetes in a large U.K. primary care database
    • Taylor K.S., Heneghan C.J., Farmer A.J., et al. All-cause and cardiovascular mortality in middle-aged people with Type 2 diabetes compared with people without diabetes in a large U.K. primary care database. Diabetes Care 2013, 36:2366-2371.
    • (2013) Diabetes Care , vol.36 , pp. 2366-2371
    • Taylor, K.S.1    Heneghan, C.J.2    Farmer, A.J.3
  • 50
    • 77953821528 scopus 로고    scopus 로고
    • Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies
    • Sarwar N., Gao P., Seshasai S.R., et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet 2010, 375:2215-2222.
    • (2010) Lancet , vol.375 , pp. 2215-2222
    • Sarwar, N.1    Gao, P.2    Seshasai, S.R.3
  • 51
    • 79952260576 scopus 로고    scopus 로고
    • Diabetes mellitus, fasting glucose, and risk of cause-specific death
    • Seshasai S.R., Kaptoge S., Thompson A., et al. Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med 2011, 364:829-841.
    • (2011) N Engl J Med , vol.364 , pp. 829-841
    • Seshasai, S.R.1    Kaptoge, S.2    Thompson, A.3
  • 53
    • 34548329882 scopus 로고    scopus 로고
    • European guidelines on cardiovascular disease prevention in clinical practice. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice
    • Graham I., Atar D., Borch-Johnsen K., et al. European guidelines on cardiovascular disease prevention in clinical practice. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice. Eur J Cardiovasc Prev Rehabil 2007, 14(Suppl. 2):S1-S113.
    • (2007) Eur J Cardiovasc Prev Rehabil , vol.14 , Issue.SUPPL. 2
    • Graham, I.1    Atar, D.2    Borch-Johnsen, K.3
  • 54
    • 0037126526 scopus 로고    scopus 로고
    • Third report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report
    • Third report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation 2002, 106:3143-3421.
    • (2002) Circulation , vol.106 , pp. 3143-3421
  • 55
    • 84872712625 scopus 로고    scopus 로고
    • 2012 update of the Canadian Cardiovascular Society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult
    • Anderson T.J., Gregoire J., Hegele R.A., et al. 2012 update of the Canadian Cardiovascular Society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult. Can J Cardiol 2013, 29:151-167.
    • (2013) Can J Cardiol , vol.29 , pp. 151-167
    • Anderson, T.J.1    Gregoire, J.2    Hegele, R.A.3
  • 56
    • 70450081001 scopus 로고    scopus 로고
    • Major lipids, apolipoproteins, and risk of vascular disease
    • Di Angelantonio E., Sarwar N., Perry P., et al. Major lipids, apolipoproteins, and risk of vascular disease. J Am Med Assoc 2009, 302:1993-2000.
    • (2009) J Am Med Assoc , vol.302 , pp. 1993-2000
    • Di Angelantonio, E.1    Sarwar, N.2    Perry, P.3
  • 57
    • 79958148945 scopus 로고    scopus 로고
    • Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management
    • Chapman M.J., Ginsberg H.N., Amarenco P., et al. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. Eur Heart J 2011, 32:1345-1361.
    • (2011) Eur Heart J , vol.32 , pp. 1345-1361
    • Chapman, M.J.1    Ginsberg, H.N.2    Amarenco, P.3
  • 60
    • 0034771277 scopus 로고    scopus 로고
    • The national glycohemoglobin standardization program: a five-year progress report
    • Little R.R., Rohlfing C.L., Wiedmeyer H.M., et al. The national glycohemoglobin standardization program: a five-year progress report. Clin Chem 2001, 47:1985-1992.
    • (2001) Clin Chem , vol.47 , pp. 1985-1992
    • Little, R.R.1    Rohlfing, C.L.2    Wiedmeyer, H.M.3
  • 61
    • 84876470858 scopus 로고    scopus 로고
    • Revisiting the links between glycaemia, diabetes and cardiovascular disease
    • Sattar N. Revisiting the links between glycaemia, diabetes and cardiovascular disease. Diabetologia 2013, 56:686-695.
    • (2013) Diabetologia , vol.56 , pp. 686-695
    • Sattar, N.1
  • 62
    • 79952600167 scopus 로고    scopus 로고
    • Impact of diabetes on cardiovascular disease risk and all-cause mortality in older men: Influence of age at onset, diabetes duration, and established and novel risk factors
    • Wannamethee S.G., Shaper A.G., Whincup P.H., et al. Impact of diabetes on cardiovascular disease risk and all-cause mortality in older men: Influence of age at onset, diabetes duration, and established and novel risk factors. Arch Intern Med 2011, 171:404-410.
    • (2011) Arch Intern Med , vol.171 , pp. 404-410
    • Wannamethee, S.G.1    Shaper, A.G.2    Whincup, P.H.3
  • 63
    • 84866066114 scopus 로고    scopus 로고
    • Diabetic retinopathy at diagnosis of type 2 diabetes in Scotland
    • Looker H.C., Nyangoma S.O., Cromie D., et al. Diabetic retinopathy at diagnosis of type 2 diabetes in Scotland. Diabetologia 2012, 55:2335-2342.
    • (2012) Diabetologia , vol.55 , pp. 2335-2342
    • Looker, H.C.1    Nyangoma, S.O.2    Cromie, D.3
  • 64
    • 63649124233 scopus 로고    scopus 로고
    • Tools for predicting the risk of type 2 diabetes in daily practice
    • Schwarz P.E., Li J., Lindstrom J., et al. Tools for predicting the risk of type 2 diabetes in daily practice. Horm Metab Res 2009, 41:86-97.
    • (2009) Horm Metab Res , vol.41 , pp. 86-97
    • Schwarz, P.E.1    Li, J.2    Lindstrom, J.3
  • 65
    • 84866607803 scopus 로고    scopus 로고
    • Prediction models for risk of developing type 2 diabetes: systematic literature search and independent external validation study
    • Abbasi A., Peelen L.M., Corpeleijn E., et al. Prediction models for risk of developing type 2 diabetes: systematic literature search and independent external validation study. Brit Med J 2012, 345:e5900.
    • (2012) Brit Med J , vol.345
    • Abbasi, A.1    Peelen, L.M.2    Corpeleijn, E.3
  • 66
    • 84864381165 scopus 로고    scopus 로고
    • Risk identification and interventions to prevent type 2 diabetes in adults at high risk: summary of NICE guidance
    • Chatterton H., Younger T., Fischer A., et al. Risk identification and interventions to prevent type 2 diabetes in adults at high risk: summary of NICE guidance. Brit Med J 2012, 345:e4624.
    • (2012) Brit Med J , vol.345
    • Chatterton, H.1    Younger, T.2    Fischer, A.3
  • 67
    • 70449517253 scopus 로고    scopus 로고
    • 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study
    • Knowler W.C., Fowler S.E., Hamman R.F., et al. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet 2009, 374:1677-1686.
    • (2009) Lancet , vol.374 , pp. 1677-1686
    • Knowler, W.C.1    Fowler, S.E.2    Hamman, R.F.3
  • 68
    • 0037034257 scopus 로고    scopus 로고
    • Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
    • Knowler W.C., Barrett-Connor E., Fowler S.E., et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002, 346:393-403.
    • (2002) N Engl J Med , vol.346 , pp. 393-403
    • Knowler, W.C.1    Barrett-Connor, E.2    Fowler, S.E.3
  • 69
    • 33748748206 scopus 로고    scopus 로고
    • Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial
    • Gerstein H.C., Yusuf S., Bosch J., et al. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 2006, 368:1096-1105.
    • (2006) Lancet , vol.368 , pp. 1096-1105
    • Gerstein, H.C.1    Yusuf, S.2    Bosch, J.3
  • 70
    • 0030935652 scopus 로고    scopus 로고
    • Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study
    • Pan X.R., Li G.W., Hu Y.H., et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care 1997, 20:537-544.
    • (1997) Diabetes Care , vol.20 , pp. 537-544
    • Pan, X.R.1    Li, G.W.2    Hu, Y.H.3
  • 71
    • 33751366229 scopus 로고    scopus 로고
    • Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study
    • Lindstrom J., Ilanne-Parikka P., Peltonen M., et al. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study. Lancet 2006, 368:1673-1679.
    • (2006) Lancet , vol.368 , pp. 1673-1679
    • Lindstrom, J.1    Ilanne-Parikka, P.2    Peltonen, M.3
  • 72
    • 0031851427 scopus 로고    scopus 로고
    • No excess 12-year mortality in men with impaired glucose tolerance who participated in the Malmo Preventive Trial with diet and exercise
    • Eriksson K.F., Lindgarde F. No excess 12-year mortality in men with impaired glucose tolerance who participated in the Malmo Preventive Trial with diet and exercise. Diabetologia 1998, 41:1010-1016.
    • (1998) Diabetologia , vol.41 , pp. 1010-1016
    • Eriksson, K.F.1    Lindgarde, F.2
  • 73
    • 79953232077 scopus 로고    scopus 로고
    • Pioglitazone for diabetes prevention in impaired glucose tolerance
    • DeFronzo R.A., Tripathy D., Schwenke D.C., et al. Pioglitazone for diabetes prevention in impaired glucose tolerance. N Engl J Med 2011, 364:1104-1115.
    • (2011) N Engl J Med , vol.364 , pp. 1104-1115
    • DeFronzo, R.A.1    Tripathy, D.2    Schwenke, D.C.3
  • 74
    • 84900812933 scopus 로고    scopus 로고
    • Management of dyslipidemia in adults with diabetes
    • American Diabetes Association
    • American Diabetes Association Management of dyslipidemia in adults with diabetes. Diabetes Care 2011, 34:S12-S47.
    • (2011) Diabetes Care , vol.34
  • 75
    • 65649106228 scopus 로고    scopus 로고
    • Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials
    • Ray K.K., Seshasai S.R., Wijesuriya S., et al. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet 2009, 373:1765-1772.
    • (2009) Lancet , vol.373 , pp. 1765-1772
    • Ray, K.K.1    Seshasai, S.R.2    Wijesuriya, S.3
  • 76
    • 84894900806 scopus 로고    scopus 로고
    • Metformin for non-diabetic patients with coronary heart disease (the CAMERA study): a randomised controlled trial
    • Preiss D., Lloyd S.M., Ford I., et al. Metformin for non-diabetic patients with coronary heart disease (the CAMERA study): a randomised controlled trial. Lancet Diabetes Endocrinol 2013, 10.1016/S2213-8587(13)70152-9.
    • (2013) Lancet Diabetes Endocrinol
    • Preiss, D.1    Lloyd, S.M.2    Ford, I.3
  • 77
    • 84872905539 scopus 로고    scopus 로고
    • Pioglitazone slows progression of atherosclerosis in prediabetes independent of changes in cardiovascular risk factors
    • Saremi A., Schwenke D.C., Buchanan T.A., et al. Pioglitazone slows progression of atherosclerosis in prediabetes independent of changes in cardiovascular risk factors. Arterioscler Thromb Vasc Biol 2013, 33:393-399.
    • (2013) Arterioscler Thromb Vasc Biol , vol.33 , pp. 393-399
    • Saremi, A.1    Schwenke, D.C.2    Buchanan, T.A.3
  • 78
    • 84871921229 scopus 로고    scopus 로고
    • Cardiovascular event reduction versus new-onset diabetes during atorvastatin therapy: effect of baseline risk factors for diabetes
    • Waters D.D., Ho J.E., Boekholdt S.M., et al. Cardiovascular event reduction versus new-onset diabetes during atorvastatin therapy: effect of baseline risk factors for diabetes. J Am Coll Cardiol 2013, 61:148-152.
    • (2013) J Am Coll Cardiol , vol.61 , pp. 148-152
    • Waters, D.D.1    Ho, J.E.2    Boekholdt, S.M.3
  • 79
    • 84864831425 scopus 로고    scopus 로고
    • Balancing the cardiometabolic benefits and risks of statins
    • Watts G.F., Ooi E.M. Balancing the cardiometabolic benefits and risks of statins. Lancet 2012, 380:541-543.
    • (2012) Lancet , vol.380 , pp. 541-543
    • Watts, G.F.1    Ooi, E.M.2
  • 80
    • 34247617826 scopus 로고    scopus 로고
    • Effects of rosuvastatin on lipids, lipoproteins and apolipoproteins in the dyslipidaemia of diabetes
    • Betteridge D.J., Gibson J.M. Effects of rosuvastatin on lipids, lipoproteins and apolipoproteins in the dyslipidaemia of diabetes. Diabet Med 2007, 24:541-549.
    • (2007) Diabet Med , vol.24 , pp. 541-549
    • Betteridge, D.J.1    Gibson, J.M.2
  • 81
    • 4344683381 scopus 로고    scopus 로고
    • Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial
    • Colhoun H.M., Betteridge D.J., Durrington P.N., et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004, 364:685-696.
    • (2004) Lancet , vol.364 , pp. 685-696
    • Colhoun, H.M.1    Betteridge, D.J.2    Durrington, P.N.3
  • 82
    • 77949300393 scopus 로고    scopus 로고
    • Atorvastatin causes insulin resistance and increases ambient glycemia in hypercholesterolemic patients
    • Koh K.K., Quon M.J., Han S.H., et al. Atorvastatin causes insulin resistance and increases ambient glycemia in hypercholesterolemic patients. J Am Coll Cardiol 2010, 55:1209-1216.
    • (2010) J Am Coll Cardiol , vol.55 , pp. 1209-1216
    • Koh, K.K.1    Quon, M.J.2    Han, S.H.3
  • 83
    • 20044366995 scopus 로고    scopus 로고
    • High-dose atorvastatin associated with worse glycemic control: a PROVE-IT TIMI 22 substudy
    • Sabatine M.S., Wiviott S.D., Morrow D.A., et al. High-dose atorvastatin associated with worse glycemic control: a PROVE-IT TIMI 22 substudy. Circulation 2004, 110(Suppl. 3):834.
    • (2004) Circulation , vol.110 , Issue.SUPPL. 3 , pp. 834
    • Sabatine, M.S.1    Wiviott, S.D.2    Morrow, D.A.3
  • 84
    • 70350223573 scopus 로고    scopus 로고
    • Influence of statins on glucose tolerance in patients with type 2 diabetes mellitus: subanalysis of the collaborative study on hypercholesterolemia drug intervention and their benefits for atherosclerosis prevention (CHIBA study)
    • Yokote K., Saito Y. Influence of statins on glucose tolerance in patients with type 2 diabetes mellitus: subanalysis of the collaborative study on hypercholesterolemia drug intervention and their benefits for atherosclerosis prevention (CHIBA study). J Atheroscler Thromb 2009, 16:297-298.
    • (2009) J Atheroscler Thromb , vol.16 , pp. 297-298
    • Yokote, K.1    Saito, Y.2
  • 85
    • 77949479227 scopus 로고    scopus 로고
    • New evidence on pitavastatin: efficacy and safety in clinical studies
    • Teramoto T., Shimano H., Yokote K., et al. New evidence on pitavastatin: efficacy and safety in clinical studies. Expert Opin Pharmacother 2010, 11:817-828.
    • (2010) Expert Opin Pharmacother , vol.11 , pp. 817-828
    • Teramoto, T.1    Shimano, H.2    Yokote, K.3
  • 86
    • 80054859738 scopus 로고    scopus 로고
    • A large-scale study on cardio-cerebrovascular events during pitavastatin (LIVALO tablet) therapy in Japanese patients with hypercholesterolemia LIVES 5-year extension study
    • Teramoto T., Urashima M., Shimano H., et al. A large-scale study on cardio-cerebrovascular events during pitavastatin (LIVALO tablet) therapy in Japanese patients with hypercholesterolemia LIVES 5-year extension study. Jpn Pharmacol Ther 2011, 39:789-803.
    • (2011) Jpn Pharmacol Ther , vol.39 , pp. 789-803
    • Teramoto, T.1    Urashima, M.2    Shimano, H.3
  • 87
    • 79957778475 scopus 로고    scopus 로고
    • Randomized head-to-head comparison of pitavastatin, atorvastatin, and rosuvastatin for safety and efficacy (quantity and quality of LDL): the PATROL trial
    • Saku K., Zhang B., Noda K. Randomized head-to-head comparison of pitavastatin, atorvastatin, and rosuvastatin for safety and efficacy (quantity and quality of LDL): the PATROL trial. Circ J 2011, 75:1493-1505.
    • (2011) Circ J , vol.75 , pp. 1493-1505
    • Saku, K.1    Zhang, B.2    Noda, K.3
  • 88
    • 84873480550 scopus 로고    scopus 로고
    • Pitavastatin 4 mg significantly reduces LDL-P and increases HDL size compared with pravastatin 40 mg (PREVAIL US)
    • Sponseller C.A., Morgan R.E., Campbell S.E. Pitavastatin 4 mg significantly reduces LDL-P and increases HDL size compared with pravastatin 40 mg (PREVAIL US). J Clin Lipidol 2012, 6:288-289.
    • (2012) J Clin Lipidol , vol.6 , pp. 288-289
    • Sponseller, C.A.1    Morgan, R.E.2    Campbell, S.E.3
  • 89
    • 84899092930 scopus 로고    scopus 로고
    • Effect of high-dose pitavastatin on glucose homeostasis in patients at elevated risk of new-onset diabetes: insights from the CAPITAIN and PREVAIL-US studies
    • Chapman M.J., Orsoni A., Robillard P., et al. Effect of high-dose pitavastatin on glucose homeostasis in patients at elevated risk of new-onset diabetes: insights from the CAPITAIN and PREVAIL-US studies. Curr Med Res Opin 2014, 10.1185/03007995.2013.874989.
    • (2014) Curr Med Res Opin
    • Chapman, M.J.1    Orsoni, A.2    Robillard, P.3
  • 90
    • 84863092923 scopus 로고    scopus 로고
    • Deterioration of glucose homeostasis in type 2 diabetic patients one year after beginning of statins therapy
    • Bellia A., Rizza S., Lombardo M.F., et al. Deterioration of glucose homeostasis in type 2 diabetic patients one year after beginning of statins therapy. Atherosclerosis 2012, 223:197-203.
    • (2012) Atherosclerosis , vol.223 , pp. 197-203
    • Bellia, A.1    Rizza, S.2    Lombardo, M.F.3
  • 91
    • 73749087527 scopus 로고    scopus 로고
    • Differing effect of statins on insulin sensitivity in non-diabetics: a systematic review and meta-analysis
    • Baker W.L., Talati R., White C.M., et al. Differing effect of statins on insulin sensitivity in non-diabetics: a systematic review and meta-analysis. Diabetes Res Clin Pract 2010, 87:98-107.
    • (2010) Diabetes Res Clin Pract , vol.87 , pp. 98-107
    • Baker, W.L.1    Talati, R.2    White, C.M.3
  • 92
    • 84875850647 scopus 로고    scopus 로고
    • Meta-analysis of impact of different types and doses of statins on new-onset diabetes mellitus
    • Navarese E.P., Buffon A., Andreotti F., et al. Meta-analysis of impact of different types and doses of statins on new-onset diabetes mellitus. Am J Cardiol 2013, 111:1123-1130.
    • (2013) Am J Cardiol , vol.111 , pp. 1123-1130
    • Navarese, E.P.1    Buffon, A.2    Andreotti, F.3
  • 94
    • 84900816992 scopus 로고    scopus 로고
    • Pitavastatin 4 mg provides significantly greater reduction in LDL-C compared to pravastatin 40 mg with neutral effects on glucose metabolism: prespecified safety analysis from the short-term phase 4 PREVAIL US trial in patients with primary hyperlipidemia or mixed dyslipidemia
    • Kryzhanovski V., Morgan R., Sponseller C.A., Davidson M.H. Pitavastatin 4 mg provides significantly greater reduction in LDL-C compared to pravastatin 40 mg with neutral effects on glucose metabolism: prespecified safety analysis from the short-term phase 4 PREVAIL US trial in patients with primary hyperlipidemia or mixed dyslipidemia. J Am Coll Cardiol 2012, 59:E1692.
    • (2012) J Am Coll Cardiol , vol.59
    • Kryzhanovski, V.1    Morgan, R.2    Sponseller, C.A.3    Davidson, M.H.4
  • 95
    • 84900818796 scopus 로고    scopus 로고
    • Short-term and long-term effects of pitavastatin and simvastatin on fasting plasma glucose in patients with primary hyperlipidemia or mixed dyslipidemia and >=2 risk factors for CHD
    • Kryzhanovski V., Eriksson M., Hounslow N., Sponseller C.A. Short-term and long-term effects of pitavastatin and simvastatin on fasting plasma glucose in patients with primary hyperlipidemia or mixed dyslipidemia and >=2 risk factors for CHD. J Am Coll Cardiol 2012, 59:E1659.
    • (2012) J Am Coll Cardiol , vol.59
    • Kryzhanovski, V.1    Eriksson, M.2    Hounslow, N.3    Sponseller, C.A.4
  • 96
    • 84876792045 scopus 로고    scopus 로고
    • Statins and risk of diabetes: an analysis of electronic medical records to evaluate possible bias due to differential survival
    • Danaei G., Garcia Rodriguez L.A., Fernandez C.O., et al. Statins and risk of diabetes: an analysis of electronic medical records to evaluate possible bias due to differential survival. Diabetes Care 2013, 36:1236-1240.
    • (2013) Diabetes Care , vol.36 , pp. 1236-1240
    • Danaei, G.1    Garcia Rodriguez, L.A.2    Fernandez, C.O.3
  • 97
    • 84865418540 scopus 로고    scopus 로고
    • Mitochondrial dysfunction in pancreatic beta cells
    • Supale S., Li N., Brun T., et al. Mitochondrial dysfunction in pancreatic beta cells. Trends Endocrinol Metab 2012, 23:477-487.
    • (2012) Trends Endocrinol Metab , vol.23 , pp. 477-487
    • Supale, S.1    Li, N.2    Brun, T.3
  • 99
    • 79952106340 scopus 로고    scopus 로고
    • Differential metabolic effects of distinct statins
    • Koh K.K., Sakuma I., Quon M.J. Differential metabolic effects of distinct statins. Atherosclerosis 2011, 215:1-8.
    • (2011) Atherosclerosis , vol.215 , pp. 1-8
    • Koh, K.K.1    Sakuma, I.2    Quon, M.J.3
  • 100
    • 84865405481 scopus 로고    scopus 로고
    • Muscle mitochondria and insulin resistance: a human perspective
    • Hoeks J., Schrauwen P. Muscle mitochondria and insulin resistance: a human perspective. Trends Endocrinol Metab 2012, 23:444-450.
    • (2012) Trends Endocrinol Metab , vol.23 , pp. 444-450
    • Hoeks, J.1    Schrauwen, P.2
  • 101
    • 84865440201 scopus 로고    scopus 로고
    • Mitochondrial dysfunction in white adipose tissue
    • Kusminski C.M., Scherer P.E. Mitochondrial dysfunction in white adipose tissue. Trends Endocrinol Metab 2012, 23:435-443.
    • (2012) Trends Endocrinol Metab , vol.23 , pp. 435-443
    • Kusminski, C.M.1    Scherer, P.E.2
  • 102
    • 84884130876 scopus 로고    scopus 로고
    • Discontinuation of statin therapy due to muscular side effects: a survey in real life
    • Rosenbaum D., Dallongeville J., Sabouret P., et al. Discontinuation of statin therapy due to muscular side effects: a survey in real life. Nutr Metab Cardiovasc Dis 2012, 23:871-875.
    • (2012) Nutr Metab Cardiovasc Dis , vol.23 , pp. 871-875
    • Rosenbaum, D.1    Dallongeville, J.2    Sabouret, P.3
  • 103
    • 33747882182 scopus 로고    scopus 로고
    • Statin therapy induces ultrastructural damage in skeletal muscle in patients without myalgia
    • Draeger A., Monastyrskaya K., Mohaupt M., et al. Statin therapy induces ultrastructural damage in skeletal muscle in patients without myalgia. J Pathol 2006, 210:94-102.
    • (2006) J Pathol , vol.210 , pp. 94-102
    • Draeger, A.1    Monastyrskaya, K.2    Mohaupt, M.3
  • 104
    • 84865440557 scopus 로고    scopus 로고
    • Effects of statins on energy and fatigue with exertion: results from a randomized controlled trial
    • Golomb B.A., Evans M.A., Dimsdale J.E., et al. Effects of statins on energy and fatigue with exertion: results from a randomized controlled trial. Arch Intern Med 2012, 172:1180-1182.
    • (2012) Arch Intern Med , vol.172 , pp. 1180-1182
    • Golomb, B.A.1    Evans, M.A.2    Dimsdale, J.E.3
  • 105
    • 33846464226 scopus 로고    scopus 로고
    • Safety and efficacy of statins in Asians
    • Liao J.K. Safety and efficacy of statins in Asians. Am J Cardiol 2007, 99:410-414.
    • (2007) Am J Cardiol , vol.99 , pp. 410-414
    • Liao, J.K.1
  • 106
    • 84862908066 scopus 로고    scopus 로고
    • Statin use and risk of diabetes mellitus in postmenopausal women in the Women's Health Initiative
    • Culver A.L., Ockene I.S., Balasubramanian R., et al. Statin use and risk of diabetes mellitus in postmenopausal women in the Women's Health Initiative. Arch Intern Med 2012, 172:144-152.
    • (2012) Arch Intern Med , vol.172 , pp. 144-152
    • Culver, A.L.1    Ockene, I.S.2    Balasubramanian, R.3
  • 107
    • 0030070566 scopus 로고    scopus 로고
    • Cholesterol and coronary heart disease mortality in elderly patients
    • Krumholz H.M., Vaccarino V., Mendes de Leon C.F., et al. Cholesterol and coronary heart disease mortality in elderly patients. J Am Med Assoc 1996, 275:110-111.
    • (1996) J Am Med Assoc , vol.275 , pp. 110-111
    • Krumholz, H.M.1    Vaccarino, V.2    Mendes de Leon, C.F.3
  • 108
    • 33644662738 scopus 로고    scopus 로고
    • Hydroxymethylglutaryl-CoA reductase inhibitors in older persons with acute myocardial infarction: evidence for an age-statin interaction
    • Foody J.M., Rathore S.S., Galusha D., et al. Hydroxymethylglutaryl-CoA reductase inhibitors in older persons with acute myocardial infarction: evidence for an age-statin interaction. J Am Geriatr Soc 2006, 54:421-430.
    • (2006) J Am Geriatr Soc , vol.54 , pp. 421-430
    • Foody, J.M.1    Rathore, S.S.2    Galusha, D.3
  • 109
    • 78649647291 scopus 로고    scopus 로고
    • Statin use and lipid levels in older adults: National Health and Nutrition Examination Survey, 2001 to 2006
    • Robinson J.G., Booth B. Statin use and lipid levels in older adults: National Health and Nutrition Examination Survey, 2001 to 2006. J Clin Lipidol 2010, 4:483-490.
    • (2010) J Clin Lipidol , vol.4 , pp. 483-490
    • Robinson, J.G.1    Booth, B.2
  • 110
    • 33748147006 scopus 로고    scopus 로고
    • Thiazide diuretics, potassium, and the development of diabetes: a quantitative review
    • Zillich A.J., Garg J., Basu S., et al. Thiazide diuretics, potassium, and the development of diabetes: a quantitative review. Hypertension 2006, 48:219-224.
    • (2006) Hypertension , vol.48 , pp. 219-224
    • Zillich, A.J.1    Garg, J.2    Basu, S.3
  • 111
    • 42549160401 scopus 로고    scopus 로고
    • New onset diabetes during antihypertensive therapy
    • Alderman M.H. New onset diabetes during antihypertensive therapy. Am J Hypertens 2008, 21:493-499.
    • (2008) Am J Hypertens , vol.21 , pp. 493-499
    • Alderman, M.H.1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.